# Thomas A. Wadden

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thomas-a-wadden/

## Facts

| Field | Value |
| --- | --- |
| Citations | 75,409 |
| Field | Bariatric Surgery and Outcomes |
| h-index | 124 |
| i10-index | 429 |
| Last Known Institution | University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5026596594 |
| ORCID iD | https://orcid.org/0000-0002-0438-4609 |
| Works | 605 |

## Researcher papers

Showing 12 of 18.

- [Once-Weekly Semaglutide in Adults with Overweight or Obesity](https://scholariq.org/papers/once-weekly-semaglutide-in-adults-with-overweight-or-obesity/)
- [2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults](https://scholariq.org/papers/2013-aha-acc-tos-guideline-for-the-management-of-overweight-and-obesity-in/)
- [2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults](https://scholariq.org/papers/2013-aha-acc-tos-guideline-for-the-management-of-overweight-and-obesity-in-2/)
- [Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes](https://scholariq.org/papers/benefits-of-modest-weight-loss-in-improving-cardiovascular-risk-factors-in/)
- [Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial](https://scholariq.org/papers/semaglutide-2-4-mg-once-a-week-in-adults-with-overweight-or-obesity-and-type-2/)
- [Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-subcutaneous-semaglutide-vs-placebo-as-an-adjunct-to-intensive/)
- [Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension](https://scholariq.org/papers/weight-regain-and-cardiometabolic-effects-after-withdrawal-of-semaglutide-the/)
- [The Science of Obesity Management: An Endocrine Society Scientific Statement](https://scholariq.org/papers/the-science-of-obesity-management-an-endocrine-society-scientific-statement/)
- [Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial](https://scholariq.org/papers/two-year-effects-of-semaglutide-in-adults-with-overweight-or-obesity-the-step-5/)
- [Primary Care Physicians’ Attitudes about Obesity and Its Treatment](https://scholariq.org/papers/primary-care-physicians-attitudes-about-obesity-and-its-treatment/)
- [Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial](https://scholariq.org/papers/association-of-the-magnitude-of-weight-loss-and-changes-in-physical-fitness-with/)
- [Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes](https://scholariq.org/papers/obstructive-sleep-apnea-among-obese-patients-with-type-2-diabetes/)

## Researcher topics

- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Eating Disorders and Behaviors](https://scholariq.org/topics/eating-disorders-and-behaviors/)
- [Obesity and Health Practices](https://scholariq.org/topics/obesity-and-health-practices/)
- [Pharmacology and Obesity Treatment](https://scholariq.org/topics/pharmacology-and-obesity-treatment/)
- [Diet and metabolism studies](https://scholariq.org/topics/diet-and-metabolism-studies/)

## Researcher university

- [University of Pennsylvania](https://scholariq.org/institutions/university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.